Aethlon Medical (NASDAQ:AEMD) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Aethlon Medical (NASDAQ:AEMDFree Report) in a report released on Thursday. The brokerage issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright decreased their price target on shares of Aethlon Medical from $90.00 to $23.00 and set a buy rating on the stock in a research note on Tuesday, October 24th.

Check Out Our Latest Report on AEMD

Aethlon Medical Price Performance

Shares of AEMD stock opened at $1.74 on Thursday. The company’s fifty day simple moving average is $1.95 and its 200-day simple moving average is $2.20. The firm has a market cap of $4.33 million, a PE ratio of -0.36 and a beta of 1.88. Aethlon Medical has a 12 month low of $1.40 and a 12 month high of $7.20.

Aethlon Medical (NASDAQ:AEMDGet Free Report) last posted its quarterly earnings results on Tuesday, November 14th. The medical equipment provider reported ($1.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.35) by $0.13. On average, equities analysts predict that Aethlon Medical will post -5.34 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Aethlon Medical

A number of large investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in Aethlon Medical by 112.9% during the third quarter. Vanguard Group Inc. now owns 1,053,198 shares of the medical equipment provider’s stock worth $613,000 after buying an additional 558,596 shares in the last quarter. Renaissance Technologies LLC grew its stake in Aethlon Medical by 11.6% during the first quarter. Renaissance Technologies LLC now owns 270,297 shares of the medical equipment provider’s stock worth $395,000 after buying an additional 28,097 shares in the last quarter. Jane Street Group LLC grew its stake in Aethlon Medical by 895.7% during the fourth quarter. Jane Street Group LLC now owns 140,245 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 126,160 shares in the last quarter. Two Sigma Investments LP grew its stake in Aethlon Medical by 219.3% during the first quarter. Two Sigma Investments LP now owns 127,341 shares of the medical equipment provider’s stock worth $49,000 after buying an additional 87,458 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new stake in Aethlon Medical during the third quarter worth about $72,000. 3.02% of the stock is currently owned by institutional investors and hedge funds.

About Aethlon Medical

(Get Free Report)

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system.

Featured Stories

Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.